TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival of NOX-A12 + anti-VEGF + Radiotherapy

Fact SheetCorporate PresentationCEO Message H1 2024

Press Release 2024, September 30 06:00 p.m. TME Pharma announces appointment of Alexandra Glucksmann to supervisory board 2024, September 27 08:00 a.m. TME Pharma provides results of third exercise of Warrants Z 2024, September 19 08:00 a.m. TME Pharma announces acceptance of the NCI’s abstract on NOX-A12 in glioblastoma for presentation at the SNO 2024 Annual Meeting

Events Investor Access Paris Aram Mangasarian, Ewelina Staniuk October 16 | Paris, France BIO-Europe Dirk Eulberg, Ewelina Staniuk November 4 -6 | Stockholm, Sweden TIDES Europe Aram Mangasarian, Stefan Vonhoff November 12 - 14 | Hamburg, Germany Latest Analyst Report Invest Securities Jamila El Bougrini, PhD 2024, July 18 (EN/FR)